WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Turkish Airlines resumes flights to Afghanistan nearly 3 years after the Taliban captured Kabul
Ashley Graham puts on a busty display and shows off her curves in a plunging bathing suit in Cannes
Indonesian student designs a life in fashion
Data security in focus for safe AI use
The bodies of 4 men and 2 women were found strangled, piled up in Mexican resort of Acapulco
China, Thailand to cooperate in lunar exploration missions
Data security in focus for safe AI use
China, Cambodia to move forward in building high
Austrian leader lauds UK's efforts on migration and cites its plan for deportations to Rwanda
Cambodia commemorates 2 Chinese martyrs killed in peacekeeping mission 31 years ago
Landmark Paris trial of Syrian officials accused of torturing, killing a father and his son starts
Xi meets US secretary of state